.jpg)
Olympus expands cancer technology portfolio with $270M BioProtect acquisition
MedTech Dive reports that Olympus has agreed to acquire BioProtect for approximately $270M as part of its continued expansion within minimally invasive cancer treatment technologies. BioProtect is best known for developing a biodegradable rectal spacer used during prostate cancer radiotherapy, designed to help reduce damage to surrounding healthy tissue during treatment.
The acquisition strengthens Olympus’ growing oncology portfolio and highlights the increasing demand for technologies that improve procedural precision whilst supporting better patient outcomes. As MedTech companies continue expanding into image-guided and minimally invasive cancer care, strategic acquisitions like this underline the importance of innovation across both therapeutic devices and supportive treatment technologies.
🔗 Read the full article on MedTech Dive: Olympus expands in cancer tech with $270M buy of BioProtect
Credit for images and content: MedTech Dive
____________________________________________________________________________________________________________________________________________________________________________________________________
Cure Talent is a recruitment agency dedicated to the medical technology industry. Whether you are looking for a new role in the medical device sector or you’re an innovative medical device, digital health, or biotech company looking for staff, get in touch with the team today and explore how Cure Talent can help!